← board
CAPR
Capricor Inc.distress 4/10 · elevated risk$18.73-1%today-47% from 52w high
Rare / Genetic 1
Lead: Duchenne muscular dystrophy · est. market ~$4B (approx, global)
Revenue
pre-revenue
Liquidity
$184M
Runway
2.0 yrs
Shares 1y
+27%
Price & events
-22.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
-2.0%
1W
-36.7%
1M
-44.7%
3M
-19.3%
6M
+174.6%
1Y
+291.8%
2Y
+285.4%
5Y
+400.8%
All
Overview
- Market Cap
- $1.08B
- Volume
- 101.59K
- 52 Week Range
- $4.60 – $35.34
- Total Shares
- 57.91M
- Float Shares
- 48.55M
- Short %
- 28.11%
- % Held by Insiders
- 9.47%
- % Held by Institutions
- 59.73%
- RVOL
- 0.06x
- Beta
- 0.42
Pipeline stages · 1 programs
Deramiocel (CAP-1002)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-06-18 | Phase 3 | Deramiocel (CAP-1002)orphanrmatrare pediatricpriority review | Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases | 106 | active not recruiting |
Upcoming readouts & decisions · our signals
2 upcoming events have our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 15
- August 22, 2026Confirmed 100%PDUFAPDUFADeramiocel · Target PDUFA action dateSEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- July 29, 2026Confirmed 100%AdCommAdCommDeramiocel · FDA CTGTAC meeting to discuss BLASEC 8-K
- third quarter of 2025readoutPhase 3Deramiocel · Topline results from HOPE-3 trial expectedSEC 8-K
- third quarter of 2025regulatory submissionFiled (NDA/BLA)Deramiocel · Planned resubmission of BLA with data from Phase 3 HOPE-3 trialSEC 8-K
- August 31, 2025PDUFAPDUFAderamiocel · PDUFA target action date for BLASEC 8-K
- 2025-07-11crlDeramiocel · FDA issued Complete Response Letter citing lack of substantial evidence of effectiveness and need for additional clinical data, plus CMC issuesSEC 8-K
- 2025-03-04rolling reviewderamiocel · BLA accepted for review with Priority Review grantedSEC 8-K
- 2025-01-02partnershipderamiocel · $10M milestone payment from Nippon Shinyaku triggered by BLA submissionSEC 8-K
- by the end of 2024regulatory submissionFiled (NDA/BLA)deramiocel · Complete rolling BLA submission to FDASEC 8-K
- by end of 2024trial initiationsecondaryStealthX vaccine · Deliver StealthX vaccine to NIAID for Project NextGen trial.SEC 8-K
- 2024-10-16partnershipderamiocel · Entered underwriting agreement for public offeringSEC 8-K
- 2024-09-24fda agreementderamiocel · FDA alignment on BLA filing for deramiocel for DMD cardiomyopathy based on existing cardiac data and natural history data.SEC 8-K
- 2024-09-16partnershipderamiocel · Binding term sheet for European commercialization and distribution with Nippon Shinyaku.SEC 8-K
- 2024-09-16partnershipPrivate placement to Nippon Shinyaku: 2,798,507 shares at $5.36, gross proceeds $15M.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $54 (+186% upside) · 10 analysts
- 2026-05-13HC Wainwright & Co.Buy
- 2026-03-13Piper SandlerOverweight
- 2026-03-13HC Wainwright & Co.Buy
- 2026-03-13B. Riley SecuritiesBuy
- 2026-03-10HC Wainwright & Co.Buy
- 2025-12-15B. Riley SecuritiesBuy
Competitors — Duchenne muscular dystrophy
- EWTXEdgewise Therapeutics, Inc.$4.1B · D4
- DYNDyne Therapeutics, Inc.$3.3B · D4
- SRPTSarepta Therapeutics, Inc.$1.6B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- SLDBSolid Biosciences Inc.$777M · D4
- RGNXREGENXBIO Inc.$508M · D7
- TRDAEntrada Therapeutics, Inc.$236M · D2
- DTILPRECISION BIOSCIENCES INC$185M · D6
- PEPGPepGen Inc.$133M · D6
- CPIXCUMBERLAND PHARMACEUTICALS INC$102M · D0
Recent news
- 2026-07-23Walleye Capital LLC Acquires New Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
- 2026-07-22Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Below Two Hundred Day Moving Average - Here's Why - MarketBeat
- 2026-07-21Drilling of High Priority Targets at Wyloo Completed - GlobeNewswire
- 2026-07-21S&P 500, Dow, Nasdaq Futures Climb As Trump Says Iran Ceasefire Holds Despite Fresh Hormuz Tensions: IREN, CRWV, CAPR, TTD Stocks In Focus - Stocktwits
- 2026-07-19Investors in Capricor Therapeutics, Inc. Should Contact The Gros - GuruFocus
- 2026-07-18Can Capricor Therapeutics’ (CAPR) FDA-Linked HQ Expansion Reshape Its Risk Profile And Strategic Flexibility? - Sahm
- 2026-07-16Capricor Therapeutics (CAPR) Signs Expansion Lease Tied To Deramiocel FDA Approval - Sahm
- 2026-07-14Capricor Therapeutics (NASDAQ: CAPR) signs 171,000 sq ft San Diego HQ lease - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.